<DOC>
	<DOCNO>NCT00083161</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , etoposide , cyclophosphamide , work different way stop tumor cell divide stop grow die . Combining one chemotherapy drug may kill tumor cell . PURPOSE : This phase II trial study well give cisplatin , etoposide , cyclophosphamide together work treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Cisplatin , Etoposide , Cyclophosphamide Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety cisplatin , etoposide , cyclophosphamide patient extensive stage small cell lung cancer . - Determine effect regimen circulate endothelial cell peripheral blood patient . Secondary - Determine progression-free survival , tumor response rate , overall survival patient treat regimen . OUTLINE : This multicenter study . - Induction therapy : Patients receive cisplatin IV 30 minutes-2 hour day 1 , etoposide IV 1-2 hour day 1-3 OR etoposide IV day 1 orally twice daily day 2-3 , oral cyclophosphamide twice daily day 8-19 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Maintenance therapy : Patients receive oral cyclophosphamide twice daily absence disease progression . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer Extensive stage disease ( i.e. , disease beyond hemithorax encompass safely tolerable radiation field ) Measurable disease Concurrent CNS metastases allow provided patient remain asymptomatic Radiotherapy surgery uncontrolled symptom allow study entry PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8 g/dL ( transfusion allow ) Hepatic ALT ≤ 2 time upper limit normal ( ULN ) Bilirubin ≤ 2 time ULN Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance ≥ 60 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past year except adequately treat basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy Chemotherapy No prior chemotherapy Endocrine therapy Concurrent corticosteroid brain metastasis allow Radiotherapy See Disease Characteristics Prior radiotherapy symptomatic site allow provide target site ( ) previously irradiate No concurrent radiotherapy Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>